Affinity Asset Advisors’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
KCM
BBA
Affinity Asset Advisors's CLDX Position: Q3 2026 in Review
Affinity Asset Advisors increased its Celldex Therapeutics (CLDX) stake by 66% in Q3 2026, buying an estimated $17.6M and bringing the position to 1,160,499 shares worth $37.6M. The position accounts for 1.53% of the portfolio, ranked #21.
Affinity Asset Advisors first reported a position in CLDX in Q4 2020 and has held it in 22 quarters since. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Affinity Asset Advisors held 1,160,499 shares of Celldex Therapeutics worth $37.6M as of Q3 2026.
- Affinity Asset Advisors bought 460,499 Celldex Therapeutics shares in Q3 2026, an estimated $17.6M.
- Celldex Therapeutics made up 1.53% of Affinity Asset Advisors's portfolio in Q3 2026, its #21 holding.
- Affinity Asset Advisors first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 22 quarters since.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.